<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04112537</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL19_0460</org_study_id>
    <nct_id>NCT04112537</nct_id>
  </id_info>
  <brief_title>Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship</brief_title>
  <official_title>Dermatologic Clinical Patterns Study of Tuberous Sclerosis Complex Patients Related With Their Somatic Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tuberous Sclerosis is a rare genetic disorder that affects about one in 15,000 individuals.&#xD;
      It is part of the phacomatoses: a germline mutation of the gene Tuberous Sclerosis Complex 1&#xD;
      (TSC1) or TSC2 causes a protein dysfunction, hamartin and tuberin respectively, leading to&#xD;
      mTOR signaling pathway activation, thus tumors rise on the skin but also brain, eyes,&#xD;
      kidneys, heart.&#xD;
&#xD;
      Thanks to the advent of sequencing techniques of the human genome, genes involved were found&#xD;
      twenty years ago. Most commonly, these are de novo private mutations and autosomal dominant&#xD;
      Mendelian transmission. About 15% of patients have a phenotype corresponding to the disease&#xD;
      but no mutation is found.&#xD;
&#xD;
      Although the initial clinical description was in 1880, publications regularly describe new&#xD;
      signs in Tuberous Sclerosis, especially for skin.&#xD;
&#xD;
      Cutaneous manifestations are important in the diagnostic criteria of the disease and often&#xD;
      even the first sign of appeal. However, no data is available on the relationship between&#xD;
      genotype and dermatological phenotype.&#xD;
&#xD;
      Therefore the investigator intend to review all cutaneous finding in Tuberous Sclerosis&#xD;
      patient and try to link with their mutation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Phenotype</measure>
    <time_frame>1 day</time_frame>
    <description>Phenotype : Dermatological signs observed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genotype</measure>
    <time_frame>1day</time_frame>
    <description>Genotype : TSC1, TSC2, mosaicism</description>
  </secondary_outcome>
  <enrollment type="Actual">90</enrollment>
  <condition>Tuberous Sclerosis Complex</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients followed in Centre Hospitalier Universtaire of Montpellier for Tuberous Sclerosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        - Diagnosis of Tuberous Sclerosis Complex established of confirmed by a geneticin, with a&#xD;
        genetic study done or processing, patients accepting to be exanimated&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier BESSIS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals of Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uh Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 30, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberous Sclerosis Complex</keyword>
  <keyword>MTOR associated protein</keyword>
  <keyword>Neurocutaneous Syndromes</keyword>
  <keyword>High-Throughput Nucleotide Sequencing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberous Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

